Biomarkers in drug safety evaluation

Biomarkers in Toxicology

Volumn , Issue , 2014, Pages 923-945

  Anadón, Arturo ^a   Castellano, Víctor ^a   Martínez Larrañaga, María Rosa ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Biomarkers; Drug development; Qualification; Safety evaluation; Validation

Indexed keywords

EID: 84902225498     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-404630-6.00055-5     Document Type: Chapter

References (96)

1. Adams C.P., Brantner V.V. Spending on new drug development. Health Economics 2010, 19:130-141.
2. Albert M.A., Danielson E., Rifai N., Ridker P.M. Effects of statin therapy on C-reactive protein levels. The pravastatin inflammatory/CRP evaluation (PRINCE). A randomized trial and cohort study. JAMA 2001, 286:64-70.
3. BDWG Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95.
4. Bachorzewska-Gajewska H., Malyszko J., Sitniewska E., et al. Could neutrophil-gelatinaseassociated lipocalin and cystatin C predict the development of contrast-induced nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine values?. Kidney Blood Press Res 2007, 30:408-415.
5. Benoehr P., Krueth P., Bokemeyer C., et al. Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial. J Am Soc Nephrol 2005, 16:452-458.
6. Bindhu M., Yano B., Sekkers R.S., et al. Evaluation of organ weights for rodent and non-rodent toxicity studies: A review of regulatory guidelines and a survey of current practices. Toxicol Pathol 2007, 35:742-750.
7. Boekelheide K., Schuppe-Koistinen I. SOT/EUROTOX Debate: Biomarkers from blood and urine will replace traditional histopathological evaluation to determine diverse responses. Toxicol Sci 2012, 129:249-255.
8. Bonventre J.V., Vaidya V.S., Schmouder R., Feig P., Dieterle F. Next-generation biomarkers for detecting kidney toxicity. Nat Biotechnol 2010, 28:436-440.
9. Boelsterli U.A. Animal model of human disease in drug safety assessment. J Toxicol Sci 2003, 28:109-121.
10. Brott D., Gould S., Jones H., et al. Biomarkers of drug-induced vascular injury. Toxicol Appl Pharmacol 2005, 207:S441-S445.
11. Burkhardt J.E., Pandher K., Solter P.F., et al. Recommendations for the evaluation of pathology data in nonclinical safety biomarkers qualification studies. Toxicolog Pathol 2011, 39:1129-1137.
12. Chesney P.J., Davis J.P., Purdy W.K., Wand P.J., Chesney R.W. Clinical manifestations of toxic shock syndrome. JAMA 1981, 246:741-748.
13. Chung W.H., Hung S.I., Hong H.S., et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004, 428:486.
14. Clark I.M., Swingler T.E., Sampieri C.L., Edwards D.R. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 2008, 40:1362-1378.
15. Collins F.S. Reengineering translational science: the time is right. Sci Transl Med 2011, 3. 90cm17.
16. Cummings, J.L., Banks, S.J., Gary, R.K. et al. (2013) Alzheimer's disease drug development: translational neuroscience strategies CNS Spectr18: 199-208.
17. Desikan R., Veksler Y., Raza S., et al. Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. Br J Haematol 2002, 119:496-499.
18. Diamond J.R., Yoburn D.C. Nonoliguric acute renal failure. Arch Intern Med 1982, 142:1882-1984.
19. Dieterle F., Sistare F., Goodsaid F., et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat Biotechnol 2010, 28:455-462.
20. Dix D.J., Houck K.A., Martin M.T., et al. The ToxCast program for prioritizing toxicity testing of environmental chemicals. Tox Sci 2007, 95:5-12.
21. Dubois B., Feldman H.H., Jacova C., et al. Research criteria for the diagnosis of Alzheimer's disease: 327 revising the NINCDS-ADRDA criteria. Lancet Neurol 2005, 6:734-746.
22. EMA (2007) Committee for Medicinal Products for Human Use (CHMP). Reflection paper on pharmacogenomics samples, testing and data handling. EMEA/CHMP/PGxWP/201914/2006. 15 November 2007.
23. EMA (2011a) Qualification opinion of Alzheimer's disease novel methodologies /biomarkers for BMS-708163. EMA/CHMP/SAWP/102001/2011, 10 February 2011.
24. EMA (2011b) Reflection paper on methodological issues associated with pharmacogenomics biomarkers in relation to clinical development and patient selection. EMA/446337/2011. 9 June 2011.
25. EMEA (2005) Guidelines on Pharmacogenetics Briefing Meetings. EMEA/CHMP/2022704. March 17, 2005.
26. EMEA (2008) Committee for medicinal products for human use (CHMP). Final conclusion on the pilot joint EMEA/FDA VXDS experience on qualification of nephrotoxicity biomarkers. EMEA/679719/2008 Rev. 1.
27. Frank R., Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev 2003, 2:566-580.
28. Fuchs T.C., Hewitt P. Biomarkers for drug-induced renal damage and nephrotoxicity: an overview for applied toxicology. AAPS J 2011, 13:615-631.
29. Gad S.C. Drug Safety Evaluation 2009, John Wiley and Sons, Inc., Hoboken, New Jersey. 2nd ed.
30. Gatanaga H., Tachikawa N., Kikuchi Y., et al. Urinary beta 2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses 2006, 22:744-748.
31. Guder W.G., Hofmann W. Markers for the diagnosis and monitoring of renal tubular lesions. Clin Nephrol 1992, 38:S3-S7.
32. Guo X., Nzerue C. How to prevent, recognize, and treat drug-induced nephrotoxicity. Cleve Clin J Med 2002, 69:289-297.
33. Haase M., Bellomo R., Devarajan P., et al. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009, 54:1012-1024.
34. Han W.K., Bonventre J.V. Biologic markers for early detection of acute kidney injury. Cur Opin Crit Care 2004, 10:476-482.
35. Han W.K., Waikar S.S., Johnson A., et al. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int 2008, 73:863-869.
36. Herget-Rosenthal S., Marggraf G., Hüsing J., et al. Early detection of acute renal failure by serum cystatin C. Kidney Int 2004, 66:1115-1122.
37. Herget-Rosenthal S., Poppen D., Hüsing J., et al. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin Chem 2004, 50:552-558.
38. Hirsch R., Dent C., Pfriem H., et al. NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol 2007, 22:2089-2095.
39. Horton R., Wilming L., Rand V., et al. Gene map of the extended human MHC. Nat Rev Genet 2004, 5:889-899.
40. Hung S.I., Chung W.H., Jee S.H., et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006, 16:297-306.
41. Hunt C.M., Papay J.I., Edwards R.I., et al. Monitoring liver safety in drug development: the GSK experience. Regul Toxicol Pharmacol 2007, 49:90-100.
42. IMI (2005) The Innovative Medicines Initiative Strategic Research Agenda. Creating Biomedical R&D Leadership for Europe to Benefit Patients and Society. Draft document. European Commission, July 26, 2005.
43. Kim H., Lee J., Hyun J.W., et al. Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biol Int 2007, 31:655-662.
44. Koch W.H. Technology platforms for pharmacogenomic diagnostic assays. Nat Rev Drug Discov 2004, 3:749-761.
45. Koerbin G., Taylor L., Dutton J., et al. Aminoglycoside interference with the Dade Behring pyrogallol red-molybdate method for the measurement of total urine protein. Clin Chem 2001, 47:2183-2184.
46. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibodies of predefined specificity. Nature 1975, 256:495-497.
47. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov 2004, 3:711.
48. Kramer F., Milting H. Novel biomarkers in human terminal heart failure and under mechanical circulatory support. Biomarkers 2011, 16:S31-S41.
49. Lanning, L.L. (2006) Toxicologic pathology assessment. In Toxicological Testing Handbook: Principles, Applications, and Data Interpretation, 2nd edn, Jacobson-Kram, D., and K.A. Keller, D.A., eds. Informa Healthcare, New York, pp. 439-464.
50. Latt D., Weiss J.B., Jayson M.I. Beta 2-microglobulin levels in serum and urine of rheumatoid arthritis patients on gold therapy. Ann Rheum Dis 1981, 40:157-160.
51. Lewin D.A., Weiner M.P. Molecular biomarkers in drug development. Drug Discov Today 2004, 9:976-983.
52. Liangos O., Perianayagam M.C., Vaidya V.S., et al. Urinary N-acetyl-beta-(d)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol 2007, 18:904-912.
53. Lock E.A., Bonventre J.V. Biomarkers in translation; past, present and future. Toxicology 2008, 245:163-166.
54. MacGregor J.T., Farr S., Tucker J.D., et al. New molecular endpoints and methods for routine toxicity testing. Fundam Appl Toxicol 1995, 26:156-173.
55. Mallal S., Phillips E., Carosi G., et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008, 358:568-579.
56. Manicone A.M., McGuire J.K. Matrix metalloproteinases as modulators of inflammation. Semin Cell Dev Biol 2008, 19:34-41.
57. Marchewka Z., Kuzniar J., Dlugosz A. Enzymuria and beta2- microglobulinuria in the assessment of the influence of proteinuria on the progression of glomerulopathies. Int Urol Nephrol 2001, 33:673-676.
58. Marrer E., Dieterle F. Impact of biomarker development on drug safety assessment. Toxicol Appl Pharmacol 2010, 243:167-179.
59. Matheis K., Laurie D., Andriamandroso C., et al. A generic operational strategy to qualify translational safety biomarkers. Drug Discov Today 2011, 16:600-608.
60. Mendis G.P., Gibberd F.B., Hunt H.A. Plasma activities of hepatic enzymes in patients on anticonvulsant therapy. Seizure 1993, 2:319-323.
61. Munshi R., Johnson A., Siew E.D., et al. MCP-1 gene activation marks acute kidney injury. J Am Soc Nephrol 2011, 22:165-175.
62. Nakamura Y. Pharmacogenomics and drug toxicity. N Engl J Med 2008, 359:856-858.
63. Newsholme S.J., Thudium D.T., Gossett K.A., Watson E.S., Schwartz L.W. Evaluation of plasma von Willebrand factor as a biomarker for acute arterial damage in rats. Toxicol Pathol 2000, 28:688-693.
64. Nguyen M.T., Devarajan P. Biomarkers for the early detection of acute kidney injury. Pediatr Nephrol 2008, 23:2151-2157.
65. NTP (2006) Biomarkers for toxicology studies. September 20-21, 2006 at the NIEHS.
66. Ochieng J., Furtak V., Lukyanov P. Extracellular functions of galectin-3. Glycoconj J 2004, 19:527-535.
67. Olson H., Betton G., Robinson D., et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Reg Toxicol Pharmacol 2000, 32:56-67.
68. Parikh C.R., Jani A., Mishra J., et al. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am J Transplant 2006, 6:1639-1645.
69. Pemberton C.J., Johnson M.L., Yandle T.G., Espiner E.A. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension 2000, 36:355-359.
70. Polkinghorne K.R. Detection and measurement of urinary protein. Curr Opin Nephrol Hypertens 2006, 15:625-630.
71. Price R.G. The role of NAG (N-acetyl-beta-d-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity. Clin Nephrol 1992, 38(Suppl 1):S14-S19.
72. Price R.G. Early markers of nephrotoxicity. Comp Clin Pathol 2002, 11:2-7.
73. Proulx N.L., Akbari A., Garg A.X., et al. Measured creatinine clearance from timed urine collections substantially overestimates glomerular filtration rate in patients with liver cirrhosis: a systematic review and individual patient meta-analysis. Nephrol Dial Transplant 2005, 20:1617-1622.
74. PSTC (2008) FDA and EMEA conclude that new renal safety biomarkers are qualified for specific regulatory purposes [serial online]. Available at . http://www.cpath.org/pdf/PSTC_nephro_VXDS_summary_final.pdf.
75. Reeves W.B., Kwon O., Ramesh G. Netrin-1 and kidney injury. II. Netrin-1 is an early biomarker of acute kidney injury. Am J Physiol Renal Physiol 2008, 294:F731-F738.
76. Richmond J.M., Sibbald W.J., Linton A.M., Linton A.L. Patterns of urinary protein excretion in patients with sepsis. Nephron 1982, 31:219-223.
77. Rosalki S.B., Roberts R., Katus H.A., Giannitsis E., Ladenson J.H. Cardiac biomarkers for detection of myocardial infarction: perspectives from past to present. Clin Chem 2004, 50:2205-2213.
78. Roskos L.K., Schneider A., Vainshtein I., et al. PK-PD modeling of protein drugs: implications in assay development. Bioanalysis 2011, 3:659-675.
79. Rudolph M.G., Stanfield R.L., Wilson I.A. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 2006, 24:419-466.
80. Santella R.M. DNA damage as an intermediate biomarker in intervention studies. Proc Soc Exp Biol Med 1997, 216:166-171.
81. Schentag J.J., Plaut M.E. Patterns of urinary beta 2-microglobulin excretion by patients treated with aminoglycosides. Kidney Int 1980, 17:654-661.
82. Schetz M., Dasta J., Goldstein S., Golper T. Drug-induced acute kidney injury. Curr Opin Crit Care 2005, 11:555-565.
83. Schmid H., Henger A., Cohen C.D., et al. Gene expression profiles of podocyte-associated molecules as diagnostic markers in acquired proteinuric diseases. J Am Soc Nephrol 2003, 14:2958-2966.
84. Sharma U.C., Pokharel S., van Brakel T.J., et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004, 110:3121-3128.
85. Star R.A. Treatment of acute renal failure. Kidney Int 1998, 54:1817-1831.
86. Stockham S.L., Scott M.A. Fundamentals of Veterinary Pathology 2002, Iowa State Press, Ames, Iowa.
87. Supavekin S., Zhang W., Kucherlapati R., et al. Differential gene expression following early renal ischemia/reperfusion. Kidney Int 2003, 63:1714-1724.
88. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs?. JAMA 1999, 282:790-795.
89. Thielemans N., Lauwerys R., Bernard A. Competition between albumin and low molecular-weight proteins for renal tubular uptake in experimental nephropathies. Nephron 1994, 66:453-458.
90. Tirelli A.S., Colombo N., Cavanna G., Mangioni C., Assael B.M. Follow-up study of enzymuria and beta 2 microglobulinuria during cis-platinum treatment. Eur J Clin Pharmacol 1985, 29:313-318.
91. Urbschat A., Obermüller N., Haferkamp A. Biomarkers of kidney injury. Biomarkers 2011, 16(S1):S22-S30.
92. Waikar S.S., Betensky R.A., Bonventre J.V. Creatinine as the gold standard for kidney injury biomarker studies?. Nephrol Dial Transplant 2009, 24:3263-3265.
93. Warnock D.G., Peck C.C. A roadmap for biomarker qualification. Nat Biotechnol 2010, 28:444-445.
94. White T.J., Clark A.G., Broder S. Genome-based biomarkers for adverse drug effects, patient enrichment and prediction of drug response, and their incorporation into clinical trial design. Person Med 2006, 3:177-185.
95. Xu S., Venge P. Lipocalins as biochemicsal markers of disease. Biochim Biophys Acta 2000, 1482:298-307.
96. Zomas A., Anagnostopoulos N., Dimopoulos M.A. Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent. Bone Marrow Transplant 2000, 25:1319-1320.